PE20230108A1 - Variantes de anticuerpos caninos - Google Patents
Variantes de anticuerpos caninosInfo
- Publication number
- PE20230108A1 PE20230108A1 PE2022002420A PE2022002420A PE20230108A1 PE 20230108 A1 PE20230108 A1 PE 20230108A1 PE 2022002420 A PE2022002420 A PE 2022002420A PE 2022002420 A PE2022002420 A PE 2022002420A PE 20230108 A1 PE20230108 A1 PE 20230108A1
- Authority
- PE
- Peru
- Prior art keywords
- igg
- canine
- variants
- substitution
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REFERIDO A VARIANTES DE ANTICUERPOS CANINOS, ESPECIFICAMENTE A UNA IgG MODIFICADA QUE COMPRENDE: UN DOMINIO CONSTANTE DE LA IgG CANINA QUE COMPRENDE AL MENOS UNA SUSTITUCION DE AMINOACIDOS CON RESPECTO A UN DOMINIO CONSTANTE DE LA IgG CANINA DE TIPO SALVAJE, EN DONDE DICHA SUSTITUCION ES UNA SUSTITUCION DE ASPARAGINA EN LA POSICION 434 CON HISTIDINA (N434H); DICHA IgG MODIFICADA TIENE UNA MAYOR AFINIDAD PARA FcRn QUE LA IgG QUE TIENE EL DOMINIO CONSTANTE DE LA IgG CANINA DE TIPO SALVAJE. TAMBIEN SE REFIERE A UN POLIPEPTIDO, UNA MOLECULA DE INMUNOGLOBULINA COMO ANTI-IL31 O ANTI-NGF, Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA IgG MODIFICADA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011453P | 2020-04-17 | 2020-04-17 | |
PCT/US2021/027836 WO2021212081A1 (en) | 2020-04-17 | 2021-04-16 | Canine antibody variants |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230108A1 true PE20230108A1 (es) | 2023-01-25 |
Family
ID=75888187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002420A PE20230108A1 (es) | 2020-04-17 | 2021-04-16 | Variantes de anticuerpos caninos |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230242635A1 (es) |
EP (1) | EP4136106A1 (es) |
JP (1) | JP2023522029A (es) |
KR (1) | KR20230005156A (es) |
CN (1) | CN115996949A (es) |
AU (1) | AU2021256056A1 (es) |
BR (1) | BR112022020944A2 (es) |
CA (1) | CA3175921A1 (es) |
CL (2) | CL2022002857A1 (es) |
CO (1) | CO2022014695A2 (es) |
EC (1) | ECSP22080846A (es) |
IL (1) | IL297287A (es) |
MX (1) | MX2022012866A (es) |
PE (1) | PE20230108A1 (es) |
TW (1) | TW202204403A (es) |
WO (1) | WO2021212081A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
MX2021008144A (es) | 2019-01-03 | 2021-10-13 | Invetx Inc | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. |
BR112022022922A2 (pt) | 2020-05-11 | 2023-01-17 | Invetx Inc | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso |
MX2023000500A (es) | 2020-07-10 | 2023-04-12 | Invetx Inc | Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso. |
CN116438196A (zh) * | 2020-09-28 | 2023-07-14 | 硕腾服务有限责任公司 | 犬抗体变体 |
WO2023250284A2 (en) * | 2022-06-21 | 2023-12-28 | Zoetis Services Llc | Canine antibody mutants |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
AU2011291462A1 (en) | 2010-08-19 | 2013-03-14 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
KR20230079499A (ko) * | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
WO2018073185A1 (en) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
MX2021004313A (es) * | 2018-10-18 | 2021-05-27 | Kindred Biosciences Inc | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. |
MX2021008144A (es) * | 2019-01-03 | 2021-10-13 | Invetx Inc | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. |
US20220169740A1 (en) * | 2019-03-20 | 2022-06-02 | Kindred Biosciences, Inc. | NGF Antagonists for Medical Use |
-
2021
- 2021-04-16 CN CN202180028973.4A patent/CN115996949A/zh active Pending
- 2021-04-16 MX MX2022012866A patent/MX2022012866A/es unknown
- 2021-04-16 US US17/918,853 patent/US20230242635A1/en active Pending
- 2021-04-16 EP EP21724863.2A patent/EP4136106A1/en active Pending
- 2021-04-16 IL IL297287A patent/IL297287A/en unknown
- 2021-04-16 AU AU2021256056A patent/AU2021256056A1/en active Pending
- 2021-04-16 JP JP2022562645A patent/JP2023522029A/ja active Pending
- 2021-04-16 BR BR112022020944A patent/BR112022020944A2/pt unknown
- 2021-04-16 KR KR1020227035765A patent/KR20230005156A/ko active Search and Examination
- 2021-04-16 CA CA3175921A patent/CA3175921A1/en active Pending
- 2021-04-16 PE PE2022002420A patent/PE20230108A1/es unknown
- 2021-04-16 WO PCT/US2021/027836 patent/WO2021212081A1/en unknown
- 2021-04-19 TW TW110113947A patent/TW202204403A/zh unknown
-
2022
- 2022-10-17 CL CL2022002857A patent/CL2022002857A1/es unknown
- 2022-10-17 EC ECSENADI202280846A patent/ECSP22080846A/es unknown
- 2022-10-18 CO CONC2022/0014695A patent/CO2022014695A2/es unknown
-
2023
- 2023-11-13 CL CL2023003377A patent/CL2023003377A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP22080846A (es) | 2023-02-28 |
JP2023522029A (ja) | 2023-05-26 |
CN115996949A (zh) | 2023-04-21 |
WO2021212081A1 (en) | 2021-10-21 |
CO2022014695A2 (es) | 2022-10-21 |
AU2021256056A1 (en) | 2022-10-20 |
CL2022002857A1 (es) | 2023-06-02 |
IL297287A (en) | 2022-12-01 |
MX2022012866A (es) | 2022-11-08 |
KR20230005156A (ko) | 2023-01-09 |
CA3175921A1 (en) | 2021-10-21 |
TW202204403A (zh) | 2022-02-01 |
BR112022020944A2 (pt) | 2022-12-27 |
US20230242635A1 (en) | 2023-08-03 |
CL2023003377A1 (es) | 2024-04-19 |
EP4136106A1 (en) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230108A1 (es) | Variantes de anticuerpos caninos | |
PE20230348A1 (es) | Variantes de anticuerpos felinos | |
BR112016016416A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS | |
BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
EA202090247A1 (ru) | Антитела против cd166 и их применения | |
CL2018000238A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
BR112017006591A2 (pt) | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico | |
BR112016020065A2 (pt) | sítios específicos para modificar anticorpos para fazer imunoconjugados | |
BR112018000477A2 (pt) | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural | |
CU20180136A7 (es) | Anticuerpos monoclonales aislados que compiten por la union a tau con el anticuerpo 16g7 | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
PE20131141A1 (es) | Anticuerpo monoclonal | |
AR074427A1 (es) | Composiciones estables de anticuerpos y metodos para estabilizarlas | |
EA201291181A1 (ru) | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
PE20211214A1 (es) | Variantes de pertuzumab y su evaluacion | |
EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
EA201991464A1 (ru) | АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ | |
EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
BR112021020204A2 (pt) | Método para purificar anticorpo com região fc modificada | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso |